vs
Side-by-side financial comparison of FRANKLIN ELECTRIC CO INC (FELE) and Bio-Techne (TECH). Click either name above to swap in a different company.
FRANKLIN ELECTRIC CO INC is the larger business by last-quarter revenue ($500.4M vs $295.9M, roughly 1.7× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs 6.9%, a 5.9% gap on every dollar of revenue. On growth, FRANKLIN ELECTRIC CO INC posted the faster year-over-year revenue change (9.9% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs -4.0%).
Franklin Electric Co., Inc. is a manufacturer and distributor of products and systems focused on the movement and management of water and energy. The company offers pumps, motors, drives, and controls for use in a variety of residential, commercial, agricultural, industrial, and municipal applications. Headquartered in Fort Wayne, Indiana, the company also operates manufacturing facilities in the United States, Germany, Czech Republic, Italy, Turkey, Mexico, Brazil, Australia, South Africa, C...
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
FELE vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $500.4M | $295.9M |
| Net Profit | $34.7M | $38.0M |
| Gross Margin | 35.0% | 64.6% |
| Operating Margin | 9.6% | 18.4% |
| Net Margin | 6.9% | 12.8% |
| Revenue YoY | 9.9% | -6.4% |
| Net Profit YoY | 10.6% | 68.3% |
| EPS (diluted) | $0.77 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $500.4M | — | ||
| Q4 25 | $506.9M | $295.9M | ||
| Q3 25 | $581.7M | — | ||
| Q2 25 | $587.4M | $317.0M | ||
| Q1 25 | $455.2M | $316.2M | ||
| Q4 24 | $485.7M | $297.0M | ||
| Q3 24 | $531.4M | $289.5M | ||
| Q2 24 | $543.3M | $306.1M |
| Q1 26 | $34.7M | — | ||
| Q4 25 | $39.3M | $38.0M | ||
| Q3 25 | $16.7M | — | ||
| Q2 25 | $60.1M | $-17.7M | ||
| Q1 25 | $31.0M | $22.6M | ||
| Q4 24 | $33.7M | $34.9M | ||
| Q3 24 | $54.6M | $33.6M | ||
| Q2 24 | $59.1M | $40.6M |
| Q1 26 | 35.0% | — | ||
| Q4 25 | 33.8% | 64.6% | ||
| Q3 25 | 35.9% | — | ||
| Q2 25 | 36.1% | 62.7% | ||
| Q1 25 | 36.0% | 67.9% | ||
| Q4 24 | 33.8% | 65.3% | ||
| Q3 24 | 35.7% | 63.2% | ||
| Q2 24 | 36.8% | 66.4% |
| Q1 26 | 9.6% | — | ||
| Q4 25 | 10.2% | 18.4% | ||
| Q3 25 | 14.6% | — | ||
| Q2 25 | 15.0% | -7.5% | ||
| Q1 25 | 9.7% | 12.2% | ||
| Q4 24 | 8.9% | 16.0% | ||
| Q3 24 | 13.8% | 13.8% | ||
| Q2 24 | 14.6% | 15.0% |
| Q1 26 | 6.9% | — | ||
| Q4 25 | 7.7% | 12.8% | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | 10.2% | -5.6% | ||
| Q1 25 | 6.8% | 7.1% | ||
| Q4 24 | 6.9% | 11.7% | ||
| Q3 24 | 10.3% | 11.6% | ||
| Q2 24 | 10.9% | 13.3% |
| Q1 26 | $0.77 | — | ||
| Q4 25 | $0.87 | $0.24 | ||
| Q3 25 | $0.37 | — | ||
| Q2 25 | $1.31 | $-0.11 | ||
| Q1 25 | $0.67 | $0.14 | ||
| Q4 24 | $0.73 | $0.22 | ||
| Q3 24 | $1.17 | $0.21 | ||
| Q2 24 | $1.26 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.4M | $172.9M |
| Total DebtLower is stronger | $134.4M | $260.0M |
| Stockholders' EquityBook value | $1.3B | $2.0B |
| Total Assets | $2.0B | $2.5B |
| Debt / EquityLower = less leverage | 0.10× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $80.4M | — | ||
| Q4 25 | $99.7M | $172.9M | ||
| Q3 25 | $102.9M | — | ||
| Q2 25 | $104.6M | $162.2M | ||
| Q1 25 | $84.0M | $140.7M | ||
| Q4 24 | $220.5M | $177.5M | ||
| Q3 24 | $106.3M | $187.5M | ||
| Q2 24 | $58.1M | $152.9M |
| Q1 26 | $134.4M | — | ||
| Q4 25 | $135.2M | $260.0M | ||
| Q3 25 | $135.2M | — | ||
| Q2 25 | $14.5M | $346.0M | ||
| Q1 25 | $14.9M | $330.0M | ||
| Q4 24 | $11.6M | $300.0M | ||
| Q3 24 | $11.6M | $300.0M | ||
| Q2 24 | $87.2M | $319.0M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $2.0B | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.3B | $1.9B | ||
| Q1 25 | $1.3B | $2.0B | ||
| Q4 24 | $1.3B | $2.1B | ||
| Q3 24 | $1.3B | $2.1B | ||
| Q2 24 | $1.2B | $2.1B |
| Q1 26 | $2.0B | — | ||
| Q4 25 | $1.9B | $2.5B | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.0B | $2.6B | ||
| Q1 25 | $1.9B | $2.6B | ||
| Q4 24 | $1.8B | $2.7B | ||
| Q3 24 | $1.8B | $2.7B | ||
| Q2 24 | $1.8B | $2.7B |
| Q1 26 | 0.10× | — | ||
| Q4 25 | 0.10× | 0.13× | ||
| Q3 25 | 0.10× | — | ||
| Q2 25 | 0.01× | 0.18× | ||
| Q1 25 | 0.01× | 0.16× | ||
| Q4 24 | 0.01× | 0.14× | ||
| Q3 24 | 0.01× | 0.14× | ||
| Q2 24 | 0.07× | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FELE
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
